In this week's Biotech Scorecard newsletter, Adam Feuerstein takes on the company touting gold microdust suspended in water as an ALS treatment.
By Adam Feuerstein
May 7, 2026
Senior Writer, Biotech
Adam Feuerstein
adam.feuerstein@statnews.com
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Vivek Ramaswamy wins GOP primary for Ohio governor, CellCentric raises $220M for myeloma drug, and more biotech news
Frank Cappelleri looks at the charts on the XLV ETF and at another fund that can help investors assess where health care will go.
RBC analyst Conor McNamara told CNBC the wait might be a little longer.
